Latest News and Press Releases

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

NEW YORK, 20 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour...

Totaligent (OTCID:TGNT) successfully closed the strategic acqui-hire of the Aetherium Medical platform and team.

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research...

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in...

Kraig Labs (OTCQB: KBLB) provides additional details regarding the significant advantages of its newly developed immortalized silk gland cell platform

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder, marking the first time a SERI molecule is dosed in a patient population

Wall St analysts are rating NeOnc Technologies (NASDAQ:NTHI) a “Buy”, as institutional investors and company insiders are buying